BRIEF—Eisai previews data to be presented at ASCO 2019

Eisai says it will provide data on Lenvima (lenvatinib mesylate ) and Halaven (eribulin mesylate) at this month’s annual meeting of the American Society of Clinical Oncology (ASCO).

The firm will also present the latest information on H3B-6527 (fibroblast growth factor receptor 4 inhibitor) and H3B-6545 (selective estrogen receptor α covalent antagonist).

Poster presentations will include data from an ongoing Phase I clinical study investigating Eisai’s first antibody-drug conjugate (ADC), MORAb-202, in patients with solid tumors in Japan.

Eisai says it positions oncology as “a key therapeutic area.”